NVO
Novo Nordisk·NYSE
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 5
Bearish signal 1
Stock Price Surged Significantly
Gap Up
Gap Down
Revenue Beats Expectation
EPS Beats Expectation
RSI Oversold
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NVO
Novo Nordisk A/S
A leading global healthcare company that develops insulin analogues, human insulin, and oral antidiabetic drugs for diabetes care
Pharmaceutical
--
07/09/1981
New York Stock Exchange
69,505
12-31
Depository Receipts (Ordinary Shares)
Novo Alle 1, DK-2880 Bagsverd, Denmark
Development and sales of diabetes medical products
Novo Nordisk A/S was established in 1989 by the merger of two Danish companies, Nordisk Gentofte A/S and Novo Industri A/S. The company is a global healthcare company and a world leader in obesity and diabetes care, manufacturing and marketing of pharmaceutical products including GLP-1 receptor agonists and modern insulins. Headquartered in Denmark, it operates in about 80 countries and sells its products in about 170 countries.
Company Financials
EPS
NVO has released its 2025 Q3 earnings. EPS was reported at 0.69, versus the expected 0.78, missing expectations. The chart below visualizes how NVO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NVO has released its 2025 Q4 earnings report, with revenue of 12.44B, reflecting a YoY change of 4.57%, and net profit of 4.23B, showing a YoY change of 7.84%. The Sankey diagram below clearly presents NVO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
